The American biotechnology company Novavax reported on Tuesday, 4, that it had positive results in phase 1 of tests of its candidate for vaccine for covid-19. The company says the vaccine was well tolerated and produced a “robust” immune response in the research participants. Now, the company says the data has been subjected to peer review for a scientific publication and is now available online. After the announcement, the company’s stock fell 10.47% in the after hours in New York, at 5:50 pm (Brasília time).
In the past three months, the company’s stock has risen more than 700%. The company has never been able to successfully develop a vaccine in more than three decades of existence, but has now received funding from the Bill & Melinda Gates Foundation and the US government to seek immunization against covid-19. In addition to being successful in phase 1, a vaccine candidate must do well in phases 2 and 3 of clinical trials to be used.